Pontifax Venture leads series-A round for Eyevensys

Pontifax joins the research company's existing pool of investors, which includes Boehringer Ingelheim Venture Fund, BPI France, CapDecisif, and Inserm Transfert. 

The new round brings the total raised by Eyevensys to €10.8m, €1.9m of which was public financing provided by BPI.

As part of the transaction, Pontifax biotech analyst Ohad Hammer has joined the Eyevensys Board.

The company will use the funds raised to secure the clinical development of its main product candidate EYS606, which will be tested in ophthalmological centres in France and in the UK by the end of 2016 as part of a study into treatment for non-infectious uveitis.

Previous funding
In January 2012, CDC Entreprises via the Innobio Fund, alongside Inserm Transfert Initiative and CapDecisif Management, provided a first €1.6m round for the business. CDC invested €950,000 and Inserm Transfert invested €300,000m.

In April 2013, Boehringer Ingelheim Venture Fund invested in the group, marking the beginning of the company's next funding round, which would be completed by June that year, targeting a value in excess of €5m. Previous investors also participated in the round.

Company
Founded in Paris in 2009, Eyevensys is a biotechnology company developing a non-viral gene therapy process to treat ocular illnesses.

Eyevensys has a team of seven.

People
Eyevensys – Raffy Kazandjian (CEO).
Pontifax Venture Capital – Ohad Hammer (biotech analyst).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• France
• Healthcare
• Expansion
• France
• Venture
• BPI France
• CDC Entreprise Innovation